Gilead Slides As Sales Guidance Adds To Hep C Franchise Concerns
February 08, 2017 at 13:01 PM EST
Shares of Gilead Sciences are dropping after the company issued weaker than expected 2017 Hepatitis C virus, or HCV, drug sales guidance.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.